<DOC>
	<DOCNO>NCT01543698</DOCNO>
	<brief_summary>This multi-center , open-label , dose finding , Phase Ib dose escalation study estimate MTD ( ) and/or RP2D ( ) dual combination LGX818 MEK162 triple combination LGX818 MEK162 LEE011 , follow independently Phase II part ass clinical efficacy assess safety combination select patient population . Oral LGX818 MEK162 administer continuous schedule . Oral LEE011 administer daily three week , one week schedule . Patients treated progression disease , unacceptable toxicity develop , withdrawal informed consent , whichever occur first . A cycle define 28 day . The dose escalation part trial conduct adult patient BRAF V600-dependent advance solid tumor expect enroll least 18 patient dual combination least 12 patient triple combination . The dose escalation guide Bayesian logistic regression model ( BLRM ) . Following MTD/RP2D declaration , patient enrol three Phase II arm dual combination one Phase II arm triple combination . All patient follow 30 day safety assessment study drug discontinuation . All patient enrol Phase II part study follow survival .</brief_summary>
	<brief_title>A Phase Ib/II Study LGX818 Combination With MEK162 Adult Patients With BRAF Dependent Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically confirm diagnosis locally advance metastatic melanoma ( stage IIIB IV per American Joint Committee Cancer [ AJCC ] ) , confirm diagnosis nonresectable advanced metastatic colorectal cancer ( mCRC ) , indication upon agreement Sponsor , whose disease progress despite previous antineoplastic therapy effective standard therapy available Written documentation BRAF V600E mutation , BRAF V600 mutation Evidence measurable disease determine RECIST v1.1 World Health Organization ( WHO ) Performance Status ≤ 2 Negative serum pregnancy test within 72 hour prior first study dose woman childbearing potential Progressive disease follow prior treatment RAFinhibitors combination MEKinhibitors Symptomatic untreated leptomeningeal disease Symptomatic brain metastasis . Patients permit receive enzyme induce antiepileptic drug Known acute chronic pancreatitis History current evidence retinal disease , retinal vein occlusion ophthalmopathy Clinically significant cardiac disease Patients abnormal laboratory value Screening/baseline Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LGX818/MEK162 Previous concurrent malignancy Pregnant nursing ( lactate ) woman For addition LEE011 triple combination , congenital long QT syndrome family history unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3 , brain metastasis baseline , abnormal coagulation result PT/INR &gt; 1.5 x ULN aPTT &gt; 1.5 x ULN . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced solid tumor ,</keyword>
	<keyword>BRAF V600 mutation</keyword>
</DOC>